Price (delayed)
$0.156
Market cap
$6.2M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.1
Enterprise value
$9.98M
Viracta is a precision oncology company targeting virus-associated malignancies. The Company's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination
There are no recent dividends present for VIRX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.